Life Changing Medicine
Discovering, Developing, and Delivering Breakthrough Medications
Discover our current investigational platforms:
Dexpramipexole

An Uncommon Approach to Severe Asthma
- In development for patients with moderate-to-severe eosinophilic asthma
- 50% of asthma patients have increased levels of inflammatory eosinophils
Drugs approved for eosinophilic asthma must be injected or infused. Knopp is developing an oral medication for eosinophilic asthma.
Knopp Biosciences
A Biotechnology Company Seeking to Save Lives
- Neurological Diseases
- Immunological Conditions